Drugs / SIM0270
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07357610 | Jan → Oct 2026 expected | — | Jiangsu Simcere Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06654791 | Oct 2024 → Mar 2025 overdue | — | Jiangsu Simcere Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06536036 | Jul → Oct 2024 | — | Jiangsu Simcere Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05293964 | May 2022 → Dec 2024 overdue | breast cancer | Jiangsu Simcere Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06680921 | Nov 2024 → Aug 2028 expected | breast cancer | Jiangsu Simcere Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-12-09 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Results SABCS Voice from China | Simcere Zaiming's brain penetrating SERD molecule for advanced ER+/Her2- breast cancer SIM0270 published its first-in-human data simcere.com ↗
The preliminary findings have shown good tolerability and anti-tumor activity in patients with advanced or metastatic ER+/HER2- who have undergone multiple lines of treatment. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-12-09 | Jiangsu Simcere Pharmaceutical Co., Ltd. | SABCS Voice from China | Simcere Zaiming's brain penetrating SERD molecule for advanced ER+/Her2- breast cancer SIM0270 published its first-in-human data simcere.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SIM0270 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06654791 ↗ |
| Route | Oral | “SIM0270 is an oral, selective estrogen receptor degrader (SERD)” NCT05293964 ↗ |